Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2012, Article ID 318597, 4 pages
http://dx.doi.org/10.1155/2012/318597
Case Report

Myelofibrosis Associated with Romiplostim Treatment in a Patient with Immune Thrombocytopenia

Department of Pathology, Baystate Medical Center, Tufts University, 759 Chestnut Street, Springfield, MA 01199, USA

Received 8 December 2011; Accepted 17 January 2012

Academic Editors: S. Aref and K. Khair

Copyright © 2012 Maria Fernanda Gonzalez and Jonathan King Freeman. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. J. Kuter, G. J. Mufti, B. J. Bain, R. P. Hasserjian, W. Davis, and M. Rutstein, “Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim,” Blood, vol. 114, no. 18, pp. 3748–3756, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. D. Provan, R. Stasi, A. C. Newland et al., “International consensus report on the investigation and management of primary immune thrombocytopenia,” Blood, vol. 115, no. 2, pp. 168–186, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. T. Leung, J. Lokan, P. Turner, and C. Smith, “Reversible bone marrow reticulin fibrosis as a side effect of romiplostim therapy for the treatment of chronic refractory immune thrombocytopenia,” Pathology, vol. 43, no. 5, pp. 520–522, 2011. View at Google Scholar
  4. G. Rodgers, “Thrombocytopenia,” in Practical Diagnosis of Hematologic Disorders, C. Kjeldsberg and S. Perkins, Eds., pp. 315–326, ASCP, Singapur, 2009. View at Google Scholar
  5. L. G. Kovaleva, E. I. Pustovaia, T. I. Safonova, A. A. Riadnenko, and E. N. Kolosova, “Clinical statistics and effectiveness of different treatments of idiopathic thrombocytopenic purpura,” Terapevticheskii Arkhiv, vol. 83, no. 4, pp. 60–65, 2011. View at Google Scholar
  6. M. Khellaf, M. Michel, P. Quittet et al., “Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program,” Blood, vol. 118, no. 16, pp. 4338–4345, 2011. View at Publisher · View at Google Scholar · View at PubMed
  7. Y.-M. C. Wang, B. Sloey, T. Wong, P. Khandelwal, R. Melara, and Y.-N. Sun, “Investigation of the pharmacokinetics of romiplostim in rodents with a focus on the clearance mechanism,” Pharmaceutical Research, vol. 28, no. 8, pp. 1931–1938, 2011. View at Publisher · View at Google Scholar · View at PubMed
  8. J. M. Despotovic and R. E. Ware, “Thrombopoiesis: new ITP paradigm?” Blood, vol. 118, no. 1, pp. 1–2, 2011. View at Google Scholar
  9. R. Rayoo, N. Sharma, and W. J. van Gaal, “A case of acute stent thrombosis during treatment with the thrombopoietin receptor agonist peptide-romiplostim,” Annals of Hematology, vol. 90, no. 11, pp. 1357–1359, 2011. View at Google Scholar
  10. K. McKrae, “Immune thrombocytopenia: no longer ‘idiopathic’,” Cleveland Clinic Journal of Medicine, vol. 78, no. 6, pp. 358–373, 2011. View at Google Scholar
  11. J. Anastasi and J. Vardiman, “Primary myelofibrosis,” in Practical Diagnosis of Hematologic Disorders, C. Kjeldsberg and S. Perkins, Eds., pp. 467–485, ASCP, Singapur, 2009. View at Google Scholar